Immunovant (IMVT) News
NASDAQ: IMVTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
31.77-0.75 (-2.31%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IMVT news summary
We found 9 recent headlines mentioning Immunovant (IMVT): 1 in the past week and 6 in the past 30 days, most often from Nasdaq, GlobeNewswire, Seeking Alpha. For price context, IMVT is down 2.31% at $31.77. The most recent story, "ProKidney Names Farah Ali CMO As Phase 3 Kidney Therapy Trial Advances", was published by Nasdaq on Nov 19, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Immunovant headlines
- ProKidney Names Farah Ali CMO As Phase 3 Kidney Therapy Trial Advances(RTTNews) - ProKidney Corp. (PROK) on Wednesday announced the promotion of Farah Ali as Chief Medical Officer (CMO) to lead its clinical program as the company advances the pivotal Phase 3 PROACT 1…NasdaqABBV, AMGN, IMVT, PROK
- Immunovant (IMVT) Q2 2027 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaq
- Strength in Tech and Weakness in Crude Oil Boost StocksThe S&P 500 Index ($SPX ) (SPY ) is up +1.56% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +1.39%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +2.17%. December E-mini S&P futures…NasdaqALK, IMVT, GOOGL, AMAT
- Immunovant, Inc. Reports IMVT-1402 Clinical Updates and Financial Results for the Quarter Ended September 30, 2026Immunovant, Inc. reported clinical updates for IMVT-1402 and announced its financial results for the fiscal second quarter ended September 30, 2026. In Period 2 of its potentially registrational…Nasdaq
- Immunovant GAAP EPS of -$0.47 beats by $0.27Seeking Alpha
- Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended September 30, 2026DURHAM, N.C., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported…GlobeNewswire
- Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026DURHAM, N.C., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT ) today announced that it will report its financial results for the second fiscal quarter ended September 30, 2026 on…GlobeNewswireIMVT, ROIV
- Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law FirmNEW YORK, Oct. 12, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Immunovant, Inc. (NASDAQ: IMVT) breached their…PR Newswire
- Weekly Buzz: MESO, LLY, ANIP Win FDA Nod; KALA, HCTI Sign LOI; IMVT Halts Lupus Study(RTTNews) - Biotech and pharma companies delivered a busy slate of updates, spanning regulatory approvals, multibillion-dollar drug discovery partnerships and pivotal clinical-trial readouts across…NasdaqABBV, ABEO, AMRX, ANIP